**Supplementary Table S2:** Agreement between IHC-based and intrinsic subtype, using dichotomous biomarker IHC status

|  |  |  |  |
| --- | --- | --- | --- |
|  | **IHC subtype** | **Intrinsic subtype** |  |
| **1% HR positivity threshold** |  | **IHC definition** | **Luminal A** | **Luminal B** | **HER2-enriched** | **Basal-like** | **Total** | **Sensitivity** | **Specificity** | **Accuracy** |
| **Luminal A** | ER+ or PR+, HER2- | 148 (92) | 73 (85) | 19 (27) | 35 (26) | 275 | 92% | 56% | 69% |
| **Luminal B** | ER+ or PR+, HER2+ | 12 (8) | 12 (14) | 25 (36) | 2 (2) | 51 | 14% | 89% | 75% |
| **HER2-enriched** | ER- and PR-, HER2+ | 0 (0) | 0 (0) | 15 (21) | 4 (3) | 19 | 21% | 99% | 87% |
| **Basal-like** | ER-, PR-, HER2- | 0 (0) | 1 (1) | 11 (16) | 90 (69) | 102 | 69% | 96% | 88% |
| **Total** |  | 160 | 86 | 70 | 131 | 447 |  |  |  |
| **10% HR positivity threshold** |  | **IHC definition** | **Luminal A** | **Luminal B** | **HER2-enriched** | **Basal-like** | **Total** | **Sensitivity** | **Specificity** | **Accuracy** |
| **Luminal A** | ER+ or PR+, HER2- | 148 (92) | 71 (83) | 14 (20) | 13 (9) | 246 | 92% | 66% | 75% |
| **Luminal B** | ER+ or PR+, HER2+ | 12 (8) | 12 (14) | 17 (24) | 0 (0) | 41 | 14% | 92% | 77% |
| **HER2-enriched** | ER- and PR-, HER2+ | 0 (0) | 0 (0) | 23 (33) | 6 (5) | 29 | 33% | 98% | 88% |
| **Basal-like** | ER-, PR-, HER2- | 0 (0) | 3 (3) | 16 (23) | 112 (86) | 131 | 86% | 94% | 91% |
| **Total** |  | 160 | 86 | 70 | 131 | 447 |  |  |  |

ER=estrogen receptor; PR=progesterone receptor